BioCentury
ARTICLE | Company News

Boehringer submits new Trajenta dossier for G-BA reassessment

September 5, 2012 1:14 AM UTC

Boehringer Ingelheim GmbH (Ingelheim, Germany) submitted a new dossier for Trajenta linagliptin to Germany's Federal Joint Committee (G-BA) comparing the diabetes drug to G-BA's chosen comparator of sulfonylurea. In January, G-BA issued an unfavorable benefit rating for the drug after Boehringer used a different comparator -- sitagliptin -- in its original submission. Boehringer subsequently broke off pricing negotiations for the drug in Germany. The Institute for Quality and Efficiency in Health Care (IQWiG) is expected to publish a preliminary assessment of Trajenta by Dec. 2. G-BA's final assessment of the drug is due in late February 2013 (see BioCentury, April 27). ...